Seroepidemiological of hepatitis B among outpatients in medical institutions in Jiaxing City
LIU Minqi1, GE Rui1, HOU Zhigang1, MAO Rong1, GAO Hui1, WU Daming1, DAI Linye2
1. Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang 314050, China; 2. Haining Center for Disease Control and Prevention, Haining, Zhejiang 314400, China
Abstract：Objective To investigate the seroepidemiological characteristics of hepatitis B among outpatients in medical institutions in Jiaxing City, Zhejiang Province, so as to provide a reference for formulating region-specific hepatitis B prevention and control strategies. Methods From April to June 2024, outpatients were selected as study subjects from sentinel medical institutions in Jiaxing City. Information such as gender and age was collected. Venous blood samples were obtained and serological markers including hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B e antigen (HBeAg), hepatitis B e antibody (HBeAb), and hepatitis B core antibody (HBcAb) were tested. Positive rates of hepatitis B virus (HBV) serological markers were analyzed by genders and ages. Results A total of 1 468 outpatients were included, among whom 721 were males (49.11%) and 747 were females (50.89%). The mean age was (46.41±19.66) years. The positive rates of HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb were 7.29%, 44.75%, 1.84%, 23.50%, and 42.03%, respectively. The HBcAb positive rate in males was significantly higher than in females (46.05% vs. 38.15%, P<0.05), while no statistically significant gender differences were observed in the positive rates of other four HBV serological markers (all P>0.05). Except for HBsAb, the positive rates of the other four HBV serological markers showed statistically significant differences across different age groups (all P<0.05). Pairwise comparisons results showed that the HBsAg positive rates in age groups of 20-<40 years and 40-<60 years were 9.48% and 9.57%, respectively, which were higher than those in age groups of <20 years (1.43%) and ≥60 years (2.75%) (all P<0.05). A total of 17 HBV serological marker patterns were observed, among which the proportion of all markers negative was the highest, at 39.65%. The proportions of "small three positive" (HBsAg+, HBeAb+, HBcAb+) and "large three positive" (HBsAg+, HBeAg+, HBcAb+) patterns were 4.77% and 1.50%, respectively. Among HBsAg-positive individuals, the proportions of the "small three positive" pattern across age groups were 0, 45.45%, 90.00%, and 81.82%, while those of the "large three positive" were 0, 36.36%, 5.00%, and 0, with statistically significant differences across age groups (both P<0.05). Conclusions The positive rate of HBsAg among outpatients in medical institutions in Jiaxing City is relatively high, with a notable proportion of individuals showing either no immunity or non-response to vaccination. It is recommended to strengthen hepatitis B immunization efforts among the population aged 20-<60 years, and to enhance monitoring and interventional treatment for "small three positive" and "large three positive" patterns.
刘敏琪, 葛锐, 侯志刚, 茅蓉, 高慧, 吴大明, 戴林晔. 嘉兴市医疗机构就诊者乙型病毒性肝炎血清流行病学调查[J]. 预防医学, 2025, 37(12): 1272-1276.
LIU Minqi, GE Rui, HOU Zhigang, MAO Rong, GAO Hui, WU Daming, DAI Linye. Seroepidemiological of hepatitis B among outpatients in medical institutions in Jiaxing City. Preventive Medicine, 2025, 37(12): 1272-1276.
[1] 李娟,魏明伟,朱凤才.乙型肝炎疫苗免疫无/低应答影响因素的研究进展[J].中华流行病学杂志,2021,42(11):2066-2070. LI J,WEI M W,ZHU F C.Research progress on influencing factors of non/low response to hepatitis B vaccine immunization[J].Chin J Epidemiol,2021,42(11):2066-2070.(in Chinese) [2] World Health Organization.Global hepatitis report2024:action for access in low-and middle-income countries[EB/OL].[2025-10-14] .https://www.who.int/publications/i/item/9789240091672. [3] GBD 2013 Mortality and Causes of Death Collaborators. Global,regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death,1990-2013:a systematic analysis for the Global Burden of Disease Study 2013BD 2013 Mortality and Causes of Death Collaborators. Global,regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death,1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet,2015,385(9963):117-171. [4] 史雯,周洋,袁辰,等.2018年浙江省健康人群乙型肝炎血清流行病学调查分析[J].疾病监测,2020,35(10):904-908. SHI W,ZHOU Y,YUAN C,et al.Seroepidemiological survey of hepatitis B in healthy population in Zhejiang,2018[J].Dis Surveill,2020,35(10):904-908.(in Chinese) [5] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版)[J].中华临床感染病杂志,2022,15(6):401-427. Chinese Society of Hepatology,Chinese Medical Association,Chinese Society of Infectious Diseases,Chinese Medical Association.Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J].Chin J Clin Infect Dis,2022,15(6):401-427.(in Chinese) [6] 王福生,朱世殊,张敏,等.儿童慢性乙型肝炎防治专家共识[J].传染病信息,2024,37(2):97-112. WANG F S,ZHU S S,ZHANG M,et al.Expert consensus on the prevention and treatment of chronic hepatitis B in children[J].Infect Dis Inf,2024,37(2):97-112.(in Chinese) [7] 张婷,刘聪,郑莉,等.2020年湖北省1~69岁人群乙型肝炎血清流行病学调查[J].中国疫苗和免疫,2022,28(2):154-158. ZHANG T,LIU C,ZHENG L,et al.Seroprevalence of hepatitis B among a 1-69-year-old population of Hubei Province in 2020[J].Chin J Vaccines Immun,2022,28(2):154-158.(in Chinese) [8] 刘雨阳,赖智维,李芳彩,等.2020年湖南省1~69岁人群乙型病毒性肝炎血清流行病学调查[J].中国疫苗和免疫,2024,30(6):657-661. LIU Y Y,LAI Z W,LI F C,et al.Hepatitis B seroprevalence in people 1-69 years of age:a cross-sectional survey in Hunan Province in 2020[J].Chin J Vaccines Immun,2024,30(6):657-661.(in Chinese) [9] 王海,黄丰光,杨芬,等.2018年广东省河源市人群乙型病毒性肝炎血清流行病学调查[J].中国生物制品学杂志,2021,34(4):442-447. WANG H,HUANG F G,YANG F,et al.Seroepidemiological survey of hepatitis B among population Heyuan City,Guangdong Province,China in 2018[J].Chin J Biol,2021,34(4):442-447.(in Chinese) [10] 黄琦敏,梁亚琼,黄晓萍,等.南京市2020年1~69岁人群乙型病毒性肝炎血清流行病学调查[J].中国疫苗和免疫,2022,28(1):10-14. HUANG Q M,LIANG Y Q,HUANG X P,et al.Seroprevalence of hepatitis B among a 1-69-year-old population in Nanjing city in 2020[J].Chin J Vaccines Immun,2022,28(1):10-14.(in Chinese) [11] 刘杰,郭世成,伍凤云,等.2014—2021年江西省急性乙型病毒性肝炎流行特征分析[J].预防医学,2024,36(1):58-60. LIU J,GUO S C,WU F Y,et al.Epidemiological characteristics of acute hepatitis B in Jiangxi Province from 2014 to 2021[J].China Prev Med J,2024,36(1):58-60.(in Chinese) [12] 肖佳奇,周洁,李镯沛,等.2009—2023年苏州市急性乙型肝炎报告发病的Joinpoint回归趋势研究[J].江苏预防医学,2025,36(2):198-201. XIAO J Q,ZHOU J,LI Z P,et al.Research on Joinpoint Regression Trends of reported incidence of acute hepatitis B in Suzhou from 2009 to 2023[J].Jiangsu Prev Med,2025,36(2):198-201.(in Chinese) [13] 陈劲华,骆淑英,韦意娜,等.义乌市0~59岁人群乙型病毒性肝炎血清流行病学调查[J].预防医学,2021,33(10):1026-1029. CHEN J H,LUO S Y,WEI Y N,et al.Seroepidemiological survey of hepatitis B among people aged 0-59 years in Yiwu City[J].China Prev Med J,2021,33(10):1026-1029.(in Chinese) [14] 严娅,刘芳李,申明,等.2009—2021年成都市慢性乙型病毒性肝炎流行特征及发病趋势[J].医学动物防制,2023,39(7):639-642. YAN Y,LIU F L,SHEN M,et al.Epidemiological characteristics and incidence trend of chronic viral hepatitis B in Chengdu from 2009 to 2021[J].J Med Pest Control,2023,39(7):639-642.(in Chinese) [15] 卢小焕. 乙肝两对半和DNA联合检验在乙肝诊断中的价值及临床意义[J].包头医学,2022,46(3):32-34. LU X H.Value and clinical significance of combined detection of hepatitis B five markers and DNA in hepatitis B diagnosis[J].J Baotou Med,2022,46(3):32-34.(in Chinese) [16] 付敬敬,王彬,王钱,等.HBeAg阴性慢性HBV感染人群血清HBsAg自发清除的影响因素[J].中华医院感染学杂志,2024,34(24):3742-3748. FU J J,WANG B,WANG Q,et al.Factors influencing spontaneous seroclearance of HBsAg in HBeAg negative chronic HBV infection[J].Chin J Nosocomiol,2024,34(24):3742-3748.(in Chinese)
